L. Smith
Net worth: 8 M $ as of 2024-04-29
Career history of L. Smith
Former positions of L. Smith
| Companies | Position | Start | End |
|---|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2017-07-31 | 2020-12-14 |
| Corporate Officer/Principal | 2020-12-14 | 2024-01-30 | |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 2016-05-31 | 2017-07-31 |
| UNITED THERAPEUTICS CORPORATION | Corporate Officer/Principal | 2014-11-30 | 2016-05-31 |
Training of L. Smith
| University of New Hampshire | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
- Stock Market
- Insiders
- L. Smith
- Experience
